Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare TACROLIMUS EXTENDED-RELEASE CAPSULES (tacrolimus) and TACROLIMUS OINTMENT 0.1% (Tacrolimus) — clinical data, side effects, and patient experiences.
tacrolimus, Protopic, Prograf · Immunosuppressant
How it works
12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...
Approved for
Tacrolimus · Immunosuppressant
How it works
Other agent
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for TACROLIMUS EXTENDED-RELEASE CAPSULES vs TACROLIMUS OINTMENT 0.1%.
Both TACROLIMUS EXTENDED-RELEASE CAPSULES and TACROLIMUS OINTMENT 0.1% belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. TACROLIMUS EXTENDED-RELEASE CAPSULES is administered via Oral, whereas TACROLIMUS OINTMENT 0.1% uses Topical. Route of administration can affect onset of action and patient adherence.
TACROLIMUS EXTENDED-RELEASE CAPSULES carries 4 FDA warnings. TACROLIMUS OINTMENT 0.1% carries 1 FDA warning. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.